Stereotactic body radiotherapy for lung cancer: how much does it really cost?
BACKGROUND
Despite the lack of randomized evidence, stereotactic body radiotherapy (SBRT) is being accepted as superior to conventional radiotherapy for patients with T1-2N0 non-small-cell lung cancer in the periphery of the lung and unfit or unwilling to undergo surgery. To introduce SBRT in a system of coverage with evidence development, a correct financing had to be determined.


METHODS
A time-driven activity-based costing model for radiotherapy was developed. Resource cost calculation of all radiotherapy treatments, standard and innovative, was conducted in 10 Belgian radiotherapy centers in the second half of 2012.


RESULTS
The average cost of lung SBRT across the 10 centers (6221&OV0556;) is in the range of the average costs of standard fractionated 3D-conformal radiotherapy (5919&OV0556;) and intensity-modulated radiotherapy (7379&OV0556;) for lung cancer. Hypofractionated 3D-conformal radiotherapy and intensity-modulated radiotherapy schemes are less costly (3993&OV0556; respectively 4730&OV0556;). The SBRT cost increases with the number of fractions and is highly dependent of personnel and equipment use. SBRT cost varies more by centre than conventional radiotherapy cost, reflecting different technologies, stages in the learning curve and a lack of clear guidance in this field.


CONCLUSIONS
Time-driven activity-based costing of radiotherapy is feasible in a multicentre setup, resulting in real-life resource costs that can form the basis for correct reimbursement schemes, supporting an early yet controlled introduction of innovative radiotherapy techniques in clinical practice.
*Radiation Oncology Department, Ghent University Hospital, Ghent University, Ghent, Belgium; †Belgian Health Care Knowledge Centre (KCE), Doorbuilding, Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium; and ‡Möbius NV/SA, Kortrijksesteenweg 152, B-9830 Sint-Martens-Latem, Belgium.
Yolande
Y
Lievens
Caroline
C
Obyn
Anne-Sophie
AS
Mertens
Dries
D
Van Halewyck
Frank
F
Hulstaert
D003362:Cost-Benefit Analysis; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000191:economics* / Q000601:surgery*; D011379:Prognosis; D016634:Radiosurgery / Q000191:economics*; D011880:Radiotherapy Planning, Computer-Assisted; D050397:Radiotherapy, Intensity-Modulated / Q000191:economics*